ES2182504T3 - Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. - Google Patents

Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Info

Publication number
ES2182504T3
ES2182504T3 ES99913138T ES99913138T ES2182504T3 ES 2182504 T3 ES2182504 T3 ES 2182504T3 ES 99913138 T ES99913138 T ES 99913138T ES 99913138 T ES99913138 T ES 99913138T ES 2182504 T3 ES2182504 T3 ES 2182504T3
Authority
ES
Spain
Prior art keywords
formula
physiologically compatible
preparation
compounds
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99913138T
Other languages
English (en)
Inventor
Heinz-Werner Kleemann
Hans-Jochen Lang
Jan-Robert Schwark
Andreas Weichert
Sabine Faber
Hans-Willi Jansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of ES2182504T3 publication Critical patent/ES2182504T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47Y being a hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bifenilsulfonilcianamidas, procedimiento para su preparación y su utilización como medicamento. **(Fórmula)** Los compuestos de la Fórmula I conformes al invento y sus sales fisiológicamente compatibles se pueden utilizar en un animal, preferiblemente en un mamífero, y en particular en un ser humano como medicamentos por sí solos, en mezclas unos con otros o en forma de formulaciones farmacéuticas. Son objeto del presente invento también los compuestos de la Fórmula I y sus sales fisiológicamente compatibles para su aplicación como medicamentos, su utilización en la terapia y la profilaxis de los cuadros morbosos mencionados y su preparación de medicamentos para estos estados. Además, son objeto del presente invento formulaciones farmacéuticas, que como ingrediente activo contienen una dosis eficaz de por lo menos un compuesto de la Fórmula I y/o de una sal fisiológicamente compatible de éste, junto con sustancias de vehículo y auxiliares usuales, farmacéuticamente irreprochables. Las formulaciones farmacéuticas contienen normalmente de 0, 1 a 99 por ciento en peso, de modo preferido de 0, 5 a 95 por ciento en peso de los compuestos de la Fórmula I y/o de sus sales fisiológicamente compatibles.
ES99913138T 1998-02-04 1999-02-04 Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. Expired - Lifetime ES2182504T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19804251A DE19804251A1 (de) 1998-02-04 1998-02-04 Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (1)

Publication Number Publication Date
ES2182504T3 true ES2182504T3 (es) 2003-03-01

Family

ID=7856542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99913138T Expired - Lifetime ES2182504T3 (es) 1998-02-04 1999-02-04 Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Country Status (20)

Country Link
US (1) US6369069B1 (es)
EP (1) EP1053224B1 (es)
JP (1) JP4464559B2 (es)
KR (1) KR100595353B1 (es)
CN (1) CN1231465C (es)
AR (1) AR016448A1 (es)
AT (1) ATE222584T1 (es)
AU (1) AU758154B2 (es)
BR (1) BR9907667A (es)
CA (1) CA2319555A1 (es)
DE (2) DE19804251A1 (es)
DK (1) DK1053224T3 (es)
ES (1) ES2182504T3 (es)
HK (1) HK1034706A1 (es)
HU (1) HU224618B1 (es)
PL (1) PL342453A1 (es)
PT (1) PT1053224E (es)
RU (1) RU2247111C2 (es)
TR (1) TR200002255T2 (es)
WO (1) WO1999040064A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19820064A1 (de) 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
WO2001060818A1 (en) * 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
PL360081A1 (en) 2000-07-24 2004-09-06 Bayer Cropscience Ag Biphenyl carboxamides
JP4434745B2 (ja) 2002-01-30 2010-03-17 アムジェン インコーポレイテッド 複素環式アリールスルホンアミドベンジル化合物
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
JP5438504B2 (ja) * 2006-04-11 2014-03-12 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性ナトリウムチャンネル阻害剤として有用である組成物
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
EP0586513A1 (en) * 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
ATE222584T1 (de) 2002-09-15
AR016448A1 (es) 2001-07-04
PL342453A1 (en) 2001-06-04
BR9907667A (pt) 2000-10-24
JP2002502840A (ja) 2002-01-29
EP1053224B1 (de) 2002-08-21
TR200002255T2 (tr) 2001-06-21
JP4464559B2 (ja) 2010-05-19
AU3139899A (en) 1999-08-23
US6369069B1 (en) 2002-04-09
WO1999040064A1 (de) 1999-08-12
HUP0102576A3 (en) 2002-12-28
PT1053224E (pt) 2002-12-31
RU2247111C2 (ru) 2005-02-27
KR20010040564A (ko) 2001-05-15
CA2319555A1 (en) 1999-08-12
HUP0102576A1 (hu) 2002-03-28
CN1289321A (zh) 2001-03-28
DE59902408D1 (de) 2002-09-26
AU758154B2 (en) 2003-03-13
DK1053224T3 (da) 2002-12-23
HU224618B1 (hu) 2005-11-28
DE19804251A1 (de) 1999-08-05
KR100595353B1 (ko) 2006-07-03
CN1231465C (zh) 2005-12-14
HK1034706A1 (en) 2001-11-02
EP1053224A1 (de) 2000-11-22

Similar Documents

Publication Publication Date Title
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
AR059723A2 (es) Composicion de altas dosis de ibandronato
ES2147294T3 (es) Compuestos terapeuticos.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
SE9901573D0 (sv) New compounds
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
KR940703676A (ko) 알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)
UY27553A1 (es) Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno
AR033688A1 (es) Composicion parenteral reconstituible
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
TR200101633T2 (tr) Farmasötik bileşim
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
AU2004224788A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
MX9304197A (es) Nuevo uso de dimero de lisozina y composiciones que lo contienen.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
TR200103144T2 (tr) Yeni bileşikler